Albendazole Tab Price Manufacturing Analysis-NEWS-Dingzhou Kangquan Pharmaceutical - Professional Veterinary Medicine Manufacturer

Introduction

Albendazole is a broad-spectrum anthelmintic medication widely used in human and veterinary medicine for the treatment of parasitic worm infections. The ‘price’ dimension, while seemingly commercial, fundamentally relates to manufacturing scalability, raw material sourcing, quality control, and formulation consistency – all critical engineering parameters impacting efficacy and patient safety. Albendazole exists as a racemic mixture, and its bioavailability is notably poor, dependent on co-administration with high-fat meals. This technical guide will delve into the material science of albendazole, its manufacturing processes, performance characteristics, potential failure modes, and relevant industry standards. Understanding these factors is crucial for pharmaceutical manufacturers, quality assurance personnel, and procurement managers to ensure consistent product quality and therapeutic effectiveness. The price volatility of albendazole is closely tied to the complexities of its synthesis and stringent regulatory requirements. Therefore, a comprehensive understanding of its technical aspects is paramount for cost optimization and supply chain resilience.

Material Science & Manufacturing

Albendazole (methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate) is a benzimidazole derivative with a molecular weight of 265.3 g/mol. The active pharmaceutical ingredient (API) is a white to off-white powder, practically insoluble in water, but soluble in organic solvents like dimethyl sulfoxide (DMSO) and dimethylformamide (DMF). The polymorphism of albendazole is a critical factor in formulation development; different crystalline forms exhibit varying solubility and dissolution rates, impacting bioavailability. Manufacturing typically involves a multi-step organic synthesis starting from o-phenylenediamine. Key reaction parameters like temperature, pH, and solvent purity significantly influence the yield and purity of the final product. Purification processes, including recrystallization and chromatography, are employed to achieve pharmaceutical-grade API. Tablet formulation involves blending the API with excipients such as microcrystalline cellulose (MCC), lactose monohydrate, sodium starch glycolate, and magnesium stearate. Direct compression is a common tableting method, but requires careful control of granule size distribution and flow properties. Maintaining consistent particle size and morphology is essential for uniform drug content and dissolution. The coating process, often employing hydroxypropyl methylcellulose (HPMC), aims to improve stability, mask the bitter taste, and control drug release. Rigorous in-process controls are implemented throughout the manufacturing process to ensure adherence to Good Manufacturing Practices (GMP) and maintain product quality.

Performance & Engineering

The anthelmintic activity of albendazole stems from its selective binding to β-tubulin in parasitic worms, inhibiting microtubule polymerization and disrupting cell division. This mechanism of action effectively halts the worms' ability to absorb nutrients, ultimately leading to their demise. The efficacy of albendazole is significantly affected by its low aqueous solubility and variable absorption. Engineered formulations incorporating solubility enhancers, such as surfactants or cyclodextrins, aim to improve bioavailability. The mechanical strength of the tablets, measured by crushing hardness, must be sufficient to withstand handling and transportation without fragmentation. Friability testing assesses the tablet’s resistance to abrasion. Dissolution testing, conducted under standardized conditions (USP apparatus 1 or 2), is a critical quality control parameter, evaluating the rate and extent of drug release. Stability studies, performed under accelerated and long-term storage conditions, determine the shelf life of the product and identify potential degradation pathways. Environmental factors like temperature, humidity, and light exposure can influence albendazole’s stability. Packaging materials must provide adequate protection against these factors to maintain product integrity. Formulations targeting specific parasitic infections may require modified release profiles, necessitating sophisticated polymer coating techniques.

Technical Specifications

Parameter	Specification	Test Method	Acceptance Criteria
Assay (Albendazole content)	98.0% – 102.0%	HPLC	Complies
Related Substances	Individual Impurity ≤ 0.1%	HPLC	Complies
Loss on Drying	≤ 0.5%	Karl Fischer Titration	Complies
Heavy Metals	≤ 10 ppm	ICP-MS	Complies
Dissolution (Q10 min)	≥ 75%	USP Apparatus 2	Complies
Tablet Hardness	4-8 kg force	Tablet Hardness Tester	Complies

Failure Mode & Maintenance

Common failure modes for albendazole tablets include: 1) Cracking/Capping: Resulting from insufficient binder strength or excessive compression force. Mitigation involves optimizing excipient ratios and compression parameters. 2) Friability: Leading to powder loss during handling, caused by weak inter-particulate bonding. Improving granule cohesiveness and using higher-quality binders can address this. 3) Dissolution Failure: Often due to polymorphism changes, incomplete disintegration, or excipient incompatibility. Maintaining strict control over manufacturing processes and utilizing appropriate excipients are crucial. 4) Degradation: Albendazole can degrade under exposure to light, humidity, and high temperatures. Utilizing appropriate packaging materials (e.g., amber bottles, blister packs) and controlled storage conditions are essential. 5) Non-Uniform Drug Content: Caused by poor mixing or segregation during tableting. Ensuring adequate mixing time and employing flowable excipients can prevent this. Preventative maintenance of tableting machinery, including regular cleaning and calibration, is critical. Routine quality control testing, including assay, dissolution, and stability studies, should be performed to detect and address potential failures promptly. A robust change control system is essential for managing any modifications to the manufacturing process.

Industry FAQ

Q: What is the impact of particle size distribution of albendazole API on tablet performance?

A: Particle size distribution significantly impacts tablet performance. A narrow particle size distribution promotes better flowability during tableting, leading to more uniform tablet weight and drug content. Larger particles can contribute to capping or lamination, while very fine particles can cause sticking to the tablet punches. Optimal particle size is typically determined through formulation development and process optimization.

Q: How does the choice of excipients affect the bioavailability of albendazole?

A: The choice of excipients plays a critical role in enhancing albendazole’s bioavailability. Surfactants like sodium lauryl sulfate can improve wetting and dissolution. Solubilizers like cyclodextrins can increase drug solubility. Disintegrants like croscarmellose sodium aid in tablet breakdown. However, excipient compatibility must be carefully considered, as interactions can negatively impact drug stability and dissolution.

Q: What are the critical process parameters to control during tablet coating?

A: Critical process parameters during tablet coating include coating solution viscosity, spray rate, pan speed, inlet air temperature, and exhaust air flow. Maintaining precise control over these parameters ensures a uniform and durable coating, leading to consistent drug release and protection from environmental factors.

Q: How often should stability studies be conducted on albendazole tablets?

A: Stability studies should be conducted according to ICH guidelines. Typically, initial stability studies are performed during formulation development to determine the optimal packaging and storage conditions. Ongoing stability studies are then conducted periodically (e.g., every 6 months, annually) throughout the product’s shelf life to monitor any changes in quality or potency.

Q: What are the key considerations for packaging albendazole tablets to protect them from degradation?

A: Key considerations for packaging include protection from light, moisture, and oxygen. Amber-colored bottles or blister packs provide excellent light protection. The use of desiccants within the packaging can control humidity. Packaging materials with low oxygen permeability help prevent oxidative degradation. The packaging material must also be chemically inert and not interact with the drug product.

Conclusion

Albendazole tablet manufacturing is a complex process demanding rigorous control over material science, formulation development, and manufacturing parameters. The low bioavailability of albendazole presents a significant engineering challenge, necessitating innovative formulation strategies to enhance drug solubility and absorption. Understanding the potential failure modes and implementing robust preventative maintenance programs are critical for ensuring consistent product quality and efficacy.

Future developments in albendazole technology may focus on nanoparticle formulations, solid lipid nanoparticles, and nanoemulsions to further improve bioavailability and targeted drug delivery. Continued adherence to stringent regulatory guidelines and industry best practices will be essential for maintaining the safety and effectiveness of this vital anthelmintic medication. Ultimately, optimizing the ‘price’ of albendazole isn’t solely about cost reduction; it’s about achieving the highest possible therapeutic value through robust engineering and quality control.

Apr . 01, 2024 17:55 Back to list

Albendazole Tab Price Manufacturing Analysis